Back

State of the art in bleeding risk in atrial fibrillation.

28 August 2016 (14:00 - 14:18)
Organised by:
Congress Presentation Part of: Are you still afraid about bleeding risk of antithrombotic therapy in atrial fibrillation? Atrial fibrillation (AF) ESC Premium Access ESC Congress 2016

About the speaker

Photo
Professor Isabelle C Van Gelder

University Medical Centre Groningen, Groningen (Netherlands (The))

4 More presentations in this session

Presentation thumbnail
Bleeding risk for non-valvular AF patients prescribed warfarin, or standard doses of apixaban 5mg BID, dabigatran 150mg BID or rivaroxaban 20mg QD in real-world practice: Findings from EHR
Doctor G. Lip (Liverpool, GB)
Abstract Slides Video
Presentation thumbnail
Factors associated with quality of anticoagulation control in patients with atrial fibrillation and risk of stroke and bleeding
Mr A. Nissen Bonde (Roskilde, DK)
Abstract Slides Video
Presentation thumbnail
Major bleeding among patients with atrial fibrillation treated with rivaroxaban or warfarin in Sweden. Interim results from an on-going post-authorization study
Associate Professor L. Friberg (Bromma, SE)
Abstract Slides Video
Presentation thumbnail
Future direction for research in antithrombotic therapy in atrial fibrillation.
Professor E. Hylek (Boston, US)
Slides Video

Access the full session

Session thumbnail
Are you still afraid about bleeding risk of antithrombotic therapy in atrial fibrillation?

The Event

Event poster

ESC Congress 2016

28 August 2016 14:00 CET
You may be interested in
thumbnail
Congress Session
Stroke and bleeding risk in atrial fibrillation: walking the tight rope
25 August 2023
thumbnail
Congress Presentation
HASBLED score, frailty index or comorbidity index for bleeding risk assessment in patients with atrial fibrillation?
2 September 2019
thumbnail
Congress Presentation
Non valvular atrial fibrillation, contraindication to anticoagulation or antiplatelet therapy and heart team approach: a single centre experience
2 September 2019
thumbnail
Congress Presentation
Concomitant oral anticoagulant and antidepressant therapy in patients with atrial fibrillation and risk of stroke and bleeding: a population based cohort study
2 September 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources